Suven Life Sciences Q4 FY26 Results: Revenue Rs 1.52 Crore Operating Loss Rs 50.64 Crore Operating Margin Negative 3332 Percent

Suven Life Sciences Q4 FY26 results were announced on 13 May 2026. Suven Life Sciences Q4 FY26 net sales were Rs 1.52 crore, a marginal 3.40% improvement YoY from Rs 1.47 crore but down 45.91% QoQ from Rs 2.81 crore in Q3 FY26. Operating losses (PBDIT excluding other income) were Rs 50.64 crore in Q4 FY26, with operating margin of negative 3,332%. Employee costs of Rs 5.83 crore alone exceeded quarterly revenue by nearly four times. Other income of Rs 6.78 crore provided partial cushion. Stock declined 2.53% post results. The company is a clinical-stage CNS drug development company investing in R&D programs. Investors tracking Suven Life Sciences Q4 FY26 results will find detailed financial data, analysis, and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Suven Life Sciences Q4 FY26 Key Financial Highlights

Parameter	Q4 FY26	Reference
Net Loss	Rs loss (not specified) crore	Reference period
Revenue from Operations	Rs 1.52 crore	1.47 crore (Q4 FY25)
NSE Ticker	SUVEN	Sector: Clinical Stage Biopharma – CNS Drug Development

Screen the best stocks on the Univest Screener.

Suven Life Sciences Q4 FY26 Performance Analysis

Suven Life Sciences Q4 FY26 net sales were Rs 1.52 crore, a marginal 3.40% improvement YoY from Rs 1.47 crore but down 45.91% QoQ from Rs 2.81 crore in Q3 FY26. Operating losses (PBDIT excluding other income) were Rs 50.64 crore in Q4 FY26, with operating margin of negative 3,332%. Employee costs of Rs 5.83 crore alone exceeded quarterly revenue by nearly four times. Other income of Rs 6.78 crore provided partial cushion. Stock declined 2.53% post results. The company is a clinical-stage CNS drug development company investing in R&D programs. Investors and analysts will closely monitor management commentary on FY27 revenue outlook, margin trajectory, and capital allocation strategy following these Suven Life Sciences Q4 FY26 results.

The Suven Life Sciences Q4 FY26 results represent a challenging quarter with margin pressures for the company. Track live price, analyst ratings, and earnings updates on the Univest Screener.

Suven Life Sciences FY27 Outlook

Post Suven Life Sciences Q4 FY26 results, investor focus for FY27 will be on management guidance, margin trajectory, new order wins or business development, and sector-specific tailwinds. Management’s FY27 roadmap and guidance will be closely watched by investors.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on Suven Life Sciences Q4 FY26 Results

What is Suven Life Sciences Q4 FY26 net loss?

Ans. Suven Life Sciences Q4 FY26 net profit is Rs loss (not specified) crore.

When did Suven Life Sciences announce Q4 FY26 results?

Ans. Suven Life Sciences announced Q4 FY26 results on 13 May 2026, through its board meeting and BSE/NSE exchange filings.

What is the FY27 outlook for Suven Life Sciences?

Ans. Post Q4 FY26 results, investors will track management guidance on FY27 revenue growth, margins, and business development in the Clinical Stage Biopharma – CNS Drug Development sector.

Where can I track Suven Life Sciences Q4 FY26 live data?

Ans. Track Suven Life Sciences live price, analyst ratings, and Q4 FY26 earnings updates on the Univest Screener for real-time data and research.

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. All financial data cited is sourced from BSE/NSE exchange filings and verified news sources. Investments in securities are subject to market risk. Consult a SEBI-registered investment advisor before making any investment decision.